Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG (2013) <br />Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]py ridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)<br /><i>Journal of Medicinal Chemistry</i> <b>56</b>: 7343<br /><br />Zhao G, Kwon C, Wang A, Robertson JG, Marcinkeviciene J, Parker RA, Kirby MS, Hamann LG (2013) <br />Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>23</b>: 1622<br /><br />Wang W, Devasthale P, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Li YX, Zahler R, Kirby MS, Hamann LG (2011) <br />7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>21</b>: 6646<br /><br />Brigance RP, Meng W, Fura A, Harrity T, Wang A, Zahler R, Kirby MS, Hamann LG (2010) <br />Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>20</b>: 4395<br /><br />Meng W, Brigance RP, Chao HJ, Fura A, Harrity T, Marcinkeviciene J, O'Connor SP, Tamura JK, Xie D, Zhang Y, Klei HE, Kish K, Weigelt CA, Turdi H, Wang A, Zahler R, Kirby MS, Hamann LG (2010) <br />Discovery of 6-(Aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxa mides as Potent, Selective Dipeptidyl Peptidase-4 (DPP4) Inhibitors<br /><i>Journal of Medicinal Chemistry</i> <b>53</b>: 5620<br /><br />O'Connor SP, Wang Y, Simpkins LM, Brigance RP, Meng W, Wang A, Kirby MS, Weigelt CA, Hamann LG (2010) <br />Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>20</b>: 6273<br /><br />Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, Hamann LG, Humphreys WG, Kirby M (2009) <br />Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections<br /><i>Drug Metabolism & Disposition: The Biological Fate of Chemicals</i> <b>37</b>: 1164<br /><br />Metzler WJ, Yanchunas J, Weigelt C, Kish K, Klei HE, Xie D, Zhang Y, Corbett M, Tamura JK, He B, Hamann LG, Kirby MS, Marcinkeviciene J (2008) <br />Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation<br /><i>Protein Science</i> <b>17</b>: 240<br /><br />Simpkins LM, Bolton S, Pi Z, Sutton JC, Kwon C, Zhao G, Magnin DR, Augeri DJ, Gungor T, Rotella DP, Sun Z, Liu Y, Slusarchyk WS, Marcinkeviciene J, Robertson JG, Wang A, Robl JA, Atwal KS, Zahler RL, Parker RA, Kirby MS, Hamann LG (2007) <br />Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>17</b>: 6476<br /><br />Magnin DR, Taunk PC, Robertson JG, Wang A, Marcinkeviciene J, Kirby MS, Hamann LG (2006) <br />Seco-prolinenitrile inhibitors of dipeptidyl peptidase IV define minimal pharmacophore requirements at P1<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>16</b>: 1731<br /><br />Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG (2005) <br />Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes<br /><i>Journal of Medicinal Chemistry</i> <b>48</b>: 5025<br /><br />Zhao G, Taunk PC, Magnin DR, Simpkins LM, Robl JA, Wang A, Robertson JG, Marcinkeviciene J, Sitkoff DF, Parker RA, Kirby MS, Hamann LG (2005) <br />Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>15</b>: 3992<br /><br />Magnin DR, Robl JA, Sulsky RB, Augeri DJ, Huang Y, Simpkins LM, Taunk PC, Betebenner DA, Robertson JG, Abboa-Offei BE, Wang A, Cap M, Xin L, Tao L, Sitkoff DF, Malley MF, Gougoutas JZ, Khanna A, Huang Q, Han SP, Parker RA, Hamann LG (2004) <br />Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors<br /><i>Journal of Medicinal Chemistry</i> <b>47</b>: 2587<br /><br />